Compare ZKIN & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZKIN | NSRX |
|---|---|---|
| Founded | 2015 | 2019 |
| Country | China | Israel |
| Employees | N/A | 7 |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.5M | 25.8M |
| IPO Year | 2017 | N/A |
| Metric | ZKIN | NSRX |
|---|---|---|
| Price | $1.48 | $2.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $19.67 |
| AVG Volume (30 Days) | 9.3K | ★ 46.1K |
| Earning Date | 09-29-2025 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.93 | $1.98 |
| 52 Week High | $4.47 | $9.99 |
| Indicator | ZKIN | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 43.28 | 36.77 |
| Support Level | $1.26 | $1.98 |
| Resistance Level | $2.09 | $5.20 |
| Average True Range (ATR) | 0.19 | 0.19 |
| MACD | -0.02 | 0.11 |
| Stochastic Oscillator | 22.55 | 46.88 |
ZK International Group Co Ltd is engaged in the manufacture and marketing of metal pipes. The company is specialized in producing double-press thin-walled stainless steel tubes and fittings, carbon steel tubes and fittings, single-press tubes and fittings, and stainless-steel strips. The products are used in restaurants, hotels, hospitals, firefighting, food, beverage, ships, engines, industrial seawater desalination and systems of direct-drinking water, cold /hot water supply, city water supply, and gas of large/middle scale construction projects.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.